148 related articles for article (PubMed ID: 27908730)
21. 6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.
Han MA; Woo SM; Min KJ; Kim S; Park JW; Kim DE; Kim SH; Choi YH; Kwon TK
Chem Biol Interact; 2015 Feb; 228():69-78. PubMed ID: 25619640
[TBL] [Abstract][Full Text] [Related]
22. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
23. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
24. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
[TBL] [Abstract][Full Text] [Related]
25. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X
Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148
[TBL] [Abstract][Full Text] [Related]
26. mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.
Wu H; He D; Biswas S; Shafiquzzaman M; Zhou X; Charron J; Wang Y; Nayak BK; Habib SL; Liu H; Li B
Cancer Res; 2021 Jun; 81(12):3174-3186. PubMed ID: 33863779
[TBL] [Abstract][Full Text] [Related]
27. Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression.
Kalogirou C; Schäfer D; Krebs M; Kurz F; Schneider A; Riedmiller H; Kneitz B; Vergho D
Urol Int; 2016; 96(1):106-15. PubMed ID: 26496641
[TBL] [Abstract][Full Text] [Related]
28. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
Li F; Ma Z; Guan Z; Chen Y; Wu K; Guo P; Wang X; He D; Zeng J
Int J Mol Sci; 2015 Apr; 16(4):8415-29. PubMed ID: 25884331
[TBL] [Abstract][Full Text] [Related]
29. Betulin-betulinic acid natural product based analogs as anti-cancer agents.
Jonnalagadda SC; Corsello MA; Sleet CE
Anticancer Agents Med Chem; 2013 Dec; 13(10):1477-99. PubMed ID: 23848199
[TBL] [Abstract][Full Text] [Related]
30. NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance.
Shanmugasundaram K; Nayak BK; Friedrichs WE; Kaushik D; Rodriguez R; Block K
Nat Commun; 2017 Oct; 8(1):997. PubMed ID: 29051480
[TBL] [Abstract][Full Text] [Related]
31. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
32. NKAP promotes renal cell carcinoma growth via AKT/mTOR signalling pathway.
Ma Q; Hou L; Gao X; Yan K
Cell Biochem Funct; 2020 Jul; 38(5):574-581. PubMed ID: 32032976
[TBL] [Abstract][Full Text] [Related]
33. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
[TBL] [Abstract][Full Text] [Related]
34. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
35. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K
J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237
[TBL] [Abstract][Full Text] [Related]
36. Ethanol extract of Patrinia scabiosaefolia induces the death of human renal cell carcinoma 786-O cells via SIRT-1 and mTOR signaling-mediated metabolic disruptions.
Li Z; Tang Y; Zhu S; Li D; Han X; Gu G; Xing N; Ren J; Guo Z; Jiao W; Yan L; Xu Z; Zhang W
Oncol Rep; 2018 Feb; 39(2):764-772. PubMed ID: 29251317
[TBL] [Abstract][Full Text] [Related]
37. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
39. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
40. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men.
Ribback S; Cigliano A; Kroeger N; Pilo MG; Terracciano L; Burchardt M; Bannasch P; Calvisi DF; Dombrowski F
Oncotarget; 2015 May; 6(15):13036-48. PubMed ID: 25948777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
